Pneumonia

>

Latest News

©Kateryna_Kon/stock.adobe.com
Merck's 21-Valent Adult-Specific Pneumococcal Vaccine Accrues New Phase 3 and Real World Data

March 19th 2024

The novel 21-valent pneumococcal vaccine remains on track for the FDA PDUFA date of June 17, 2024; Merck adds this new data to the body of positive evidence.

FDA Grants Priority Review to Merck BLA for Investigational 21-Valent Pneumococcal Vaccine December 19, 2023
FDA Grants Priority Review to Merck BLA for Investigational 21-Valent Pneumococcal Vaccine

December 19th 2023

Hydrocortisone Bests Other Corticosteroids for Community-Acquired Pneumonia in New Analysis / Image credit: ©Crystal Light/AdobeStock
Hydrocortisone Bests Other Corticosteroids for Community-Acquired Pneumonia in New Analysis

October 23rd 2023

Merck's 21-Valent Adult Pneumococcal Vaccine Meets Key Endpoints in Pair of Phase 3 Trials
Merck's 21-Valent Adult Pneumococcal Vaccine Meets Key Endpoints in Pair of Phase 3 Trials

August 3rd 2023

Pneumococcal Vaccines for Adults: The Devil is Still in the Details image of pneumococcus virus ©RoyaltyStockPhoto/shutterstock.com
Pneumococcal Vaccines for Adults: The Devil is Still in the Details

May 8th 2023

Video Interviews

More News

© 2024 MJH Life Sciences

All rights reserved.